Entinostat, a novel histone deacetylase inhibitor is active in B‐cell lymphoma and enhances the anti‐tumour activity of rituximab and chemotherapy agents

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|169|4|506-519

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.169, Iss.4, 2015-05, pp. : 506-519

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line

By              

International Journal of Molecular Medicine, Vol. 28, Iss. 6, 2011-01 ,pp. : 985-991

Spandidos Publications

Access to resources Recommend Favorite

Herpesviridae Viral Infections following Rituximab Combined Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma

By  

Acta Haematologica, Vol. 125, Iss. 4, 2011-02 ,pp. : 230-236

Karger

Access to resources Recommend Favorite

Rituximab, Ara-C, Dexamethasone and Oxaliplatin Is Safe and Active in Heavily Pretreated Patients with Diffuse Large B-Cell Lymphoma

By  

Oncology, Vol. 69, Iss. 6, 2006-02 ,pp. : 499-502

Karger

Access to resources Recommend Favorite

The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T‐cell lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 2, 2015-10 ,pp. : 215-226

John Wiley & Sons Inc

Access to resources Recommend Favorite

The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T‐cell lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 7-1048, Iss. 2, 2015-10 ,pp. : 215-226

John Wiley & Sons Inc

Access to resources Recommend Favorite